SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma gains on completing commissioning of phase-I for Palghar multi-product facility

16 Mar 2020 Evaluate

Bliss GVS Pharma is currently trading at Rs. 99.45, up by 0.70 points or 0.71% from its previous closing of Rs. 98.75 on the BSE.

The scrip opened at Rs. 98.80 and has touched a high and low of Rs. 99.75 and Rs. 97.90 respectively. So far 12339 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 183.65 on 02-Apr-2019 and a 52 week low of Rs. 73.90 on 23-Aug-2019.

Last one week high and low of the scrip stood at Rs. 140.00 and Rs. 82.50 respectively. The current market cap of the company is Rs. 1025.79 crore.

The promoters holding in the company stood at 41.60%, while Institutions and Non-Institutions held 27.76% and 30.64% respectively.

Bliss GVS Pharma has completed the commissioning and qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the company in terms of planned production capacity when completed.

It is equipped with state of the art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention. The unit is spread on an overall area of about 200,000 sq. ft. and is intended to further augment the production capacities for the company.

Bliss GVS Pharma is engaged in the manufacture of a wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Bliss GVS Pharma Share Price

253.40 -4.95 (-1.92%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×